PURPOSE We conducted a meta-analysis to evaluate clinically meaningful benefits and
harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia …

The great potential for NMDA receptor modulators as druggable targets in
neurodegenerative disorders has been met with limited success. Considered one of the rare …

Background Alzheimer disease (AD) is a major health problem of aging, with tremendous
burden on healthcare systems, patients, and families globally. Lecanemab, an FDA …

INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal
antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity …

Abstract Background Regulatory T cells (Tregs) maintain immune tolerance. While Treg-
mediated neuroprotective activities are now well-accepted, the lack of defined antigen …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on develo** the …

Objective We performed a systematic review and meta-analysis of the cognitive
effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods …

Background Recent clinical trials of anti-Aβ monoclonal antibodies (mAbs) in the treatment
of early Alzheimer's disease (AD) have produced encouraging cognitive and clinical results …

Amyloid fibrils cause organ and tissue dysfunction in numerous severe diseases. Despite
the prevalence and severity of amyloidoses, there is still no effective and safe anti-amyloid …

Alzheimer disease (AD) is a fatal degenerative brain disease characterized by progressive
loss of cognitive skills and the ability to perform basic activities of daily living (eg, paying …